Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 4.00
KYTH's Cash to Debt is ranked higher than
79% of the 926 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. KYTH: 4.00 )
KYTH' s 10-Year Cash to Debt Range
Min: 4   Max: No Debt
Current: 4

F-Score: 2
Z-Score: 6.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -129.99
KYTH's ROE (%) is ranked lower than
52% of the 895 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.83 vs. KYTH: -129.99 )
KYTH' s 10-Year ROE (%) Range
Min: -47.46   Max: -47.46
Current: -129.99

ROA (%) -95.86
KYTH's ROA (%) is ranked lower than
53% of the 930 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.82 vs. KYTH: -95.86 )
KYTH' s 10-Year ROA (%) Range
Min: -52.09   Max: -38.51
Current: -95.86

-52.09
-38.51
ROC (Joel Greenblatt) (%) -20155.05
KYTH's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 925 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.02 vs. KYTH: -20155.05 )
KYTH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -27136.04   Max: -3013.33
Current: -20155.05

-27136.04
-3013.33
» KYTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

KYTH Guru Trades in Q1 2014

Jim Simons 116,400 sh (+182.52%)
RS Investment Management 288,700 sh (+18.66%)
» More
Q2 2014

KYTH Guru Trades in Q2 2014

Steven Cohen 15,200 sh (unchged)
Jim Simons Sold Out
RS Investment Management 283,181 sh (-1.91%)
» More
Q3 2014

KYTH Guru Trades in Q3 2014

RS Investment Management 289,881 sh (+2.37%)
Steven Cohen Sold Out
» More
Q4 2014

KYTH Guru Trades in Q4 2014

RS Investment Management 359,371 sh (+23.97%)
» More
» Details

Insider Trades

Latest Guru Trades with KYTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 11.70
KYTH's P/B is ranked higher than
53% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. KYTH: 11.70 )
KYTH' s 10-Year P/B Range
Min: 6.69   Max: 17.83
Current: 11.7

6.69
17.83
EV-to-EBIT -7.00
KYTH's EV-to-EBIT is ranked higher than
62% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.09 vs. KYTH: -7.00 )
KYTH' s 10-Year EV-to-EBIT Range
Min: -21.8   Max: -7.3
Current: -7

-21.8
-7.3
Current Ratio 6.83
KYTH's Current Ratio is ranked higher than
90% of the 900 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.36 vs. KYTH: 6.83 )
KYTH' s 10-Year Current Ratio Range
Min: 1.81   Max: 11.36
Current: 6.83

1.81
11.36
Quick Ratio 6.83
KYTH's Quick Ratio is ranked higher than
91% of the 900 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. KYTH: 6.83 )
KYTH' s 10-Year Quick Ratio Range
Min: 1.81   Max: 11.36
Current: 6.83

1.81
11.36

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.00
KYTH's Price/Net Cash is ranked higher than
92% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. KYTH: 12.00 )
KYTH' s 10-Year Price/Net Cash Range
Min: 5.66   Max: 32.33
Current: 12

5.66
32.33
Price/Net Current Asset Value 12.00
KYTH's Price/Net Current Asset Value is ranked higher than
87% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. KYTH: 12.00 )
KYTH' s 10-Year Price/Net Current Asset Value Range
Min: 5.66   Max: 32.33
Current: 12

5.66
32.33
Price/Tangible Book 11.40
KYTH's Price/Tangible Book is ranked higher than
59% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.29 vs. KYTH: 11.40 )
KYTH' s 10-Year Price/Tangible Book Range
Min: 5.42   Max: 23.14
Current: 11.4

5.42
23.14
Earnings Yield (Greenblatt) -14.30
KYTH's Earnings Yield (Greenblatt) is ranked higher than
50% of the 927 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. KYTH: -14.30 )
KYTH' s 10-Year Earnings Yield (Greenblatt) Range
Min: -16.2   Max: 0
Current: -14.3

-16.2
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:KYT.Germany,
KYTHERA Biopharmaceuticals, Inc. was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.
» More Articles for KYTH

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Kythera reports 4Q loss Mar 02 2015
Kythera reports 4Q loss Mar 02 2015
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 02 2015
5:01 pm Kythera Biopharma reports Q4 in-line Mar 02 2015
KYTHERA Biopharmaceuticals Announces 2014 Operating Results Mar 02 2015
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 13 2015
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 11 2015
KYTHERA Acquires Worldwide Rights to Clinical Compound and Key Intellectual Property for Potential... Feb 10 2015
KYTHERA Biopharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference Feb 04 2015
KYTHERA Biopharmaceuticals Submits Drug Application in Australia for Novel Submental Contouring... Feb 04 2015
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program Feb 03 2015
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events Jan 30 2015
KYTHERA Biopharmaceuticals Announces Date of FDA Advisory Committee Review of ATX-101 for the... Jan 23 2015
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program Jan 20 2015
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jan 06 2015
KYTHERA Biopharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 05 2015
KYTHERA Biopharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 05 2015
KYTHERA Biopharmaceuticals Appoints Hollings C. Renton to Board of Directors Jan 05 2015
KYTHERA Biopharmaceuticals Appoints Hollings C. Renton to Board of Directors Jan 05 2015
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program Dec 12 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK